Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rat...

RBC Capital analyst Gregory Renza initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rating and annou...

Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibo...

TD Cowen analyst Yaron Werber initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rating.

Three additional patients with Fanconi Anemia treated with briquilimab prior to stem cell transplantAll six patients with Fanco...

Oppenheimer analyst Jay Olson maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $80 price target.

Highlights for 2023 and Recent Weeks Successfully completed an underwritten offering of 3,900,000 shares of its common stock...

Fiscal 2023 Financial Results Cash and cash equivalents as of December 31, 2023, totaled $86.9 million.   Research and...

 Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antib...